Company
Genomma Lab Internacional, S.A.B. de C.V.
Headquarters: Mexico City, DF, Mexico
Employees: 2,221
Market Cap
MX$20.10 Billion
MXN as of July 1, 2025
US$1.07 Billion
Genomma Lab Internacional, S.A.B. de C.V. Categories
Mexico Healthcare Drug Manufacturers—Specialty & GenericMexico Healthcare Mexico Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. It offers skin care products under the Cicatricure, Asepxia, and Teatrical brands; hair care products under the Vanart, Medicasp, Tío Nacho, and Sistema GB brands; razor products under the Groomen brand; hydrating beverage under the Suerox brand; and nutritional products for child under the Novamil brand. The company also provides pain relief products under the Alliviax brand; cough and cold medicines under the Tukol and Next brands; and antibacterial products under the Bufferin, XL-3, and Next-AB brands. In addition, it offers HIV diagnosis product under the OraQuick brand. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | MX$18.82 B |
| EBITDA | MX$4.76 B |
| Gross Profit TTM | MX$11.96 B |
| Profit Margin | 11.79% |
| Operating Margin | 21.80% |
| Quarterly Revenue Growth | 5.00% |
Stocks & Indices
Genomma Lab Internacional, S.A.B. de C.V. has the following listings and related stock indices.
Stock: BMV: LABB wb_incandescent
Stock: FSX: GEKA wb_incandescent